Treatment of Obsessive Compulsive Disorder in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Serotonin reuptake inhibitors management

"Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI."

BEHAVIORAL

Cognitive behavioral therapy by a psychologist

CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.

BEHAVIORAL

Instructional cognitive behavioral therapy by a psychiatrist

"The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy."

Trial Locations (3)

19104

University of Pennsylvania, The Center for the Treatment and Study of Anxiety, Philadelphia

27705

Duke Child and Family Study Center, Durham

02903

Rhode Island Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Duke University

OTHER

NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children | Biotech Hunter | Biotech Hunter